It’s good to talk, NICE says to pharma industry groupNICE has entered into a new dialogue with industry to highlight the benefits of its early scientific advice Share XIt’s good to talk, NICE says to pharma industry grouphttps://pharmaphorum.com/views-analysis-market-access/its-good-to-talk-nice-says-to-pharma-industry-group/
NHS England improves offer to Vertex over CF drugsNHS officials in England have made an improved two-year pricing deal to Vertex Pharmaceuticals in a bid to Share XNHS England improves offer to Vertex over CF drugshttps://pharmaphorum.com/news/nhs-england-improves-offer-to-vertex-over-cf-drugs/
NHS chief hails SMA drug deal – and was that a swipe at Vertex?Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s Share XNHS chief hails SMA drug deal – and was that a swipe at Vertex?https://pharmaphorum.com/news/nhs-chief-hails-sma-drug-deal-and-was-that-a-swipe-at-vertex/
Market access round-up: the UK opens up to innovationWhen it comes to market access in the UK, the public’s eye has mostly been on the ongoing Share XMarket access round-up: the UK opens up to innovationhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-the-uk-opens-up-to-innovation/
NICE backs Ocrevus for PPMS in England – but with caveatsPatients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for Share XNICE backs Ocrevus for PPMS in England – but with caveatshttps://pharmaphorum.com/news/nice-backs-ocrevus-for-ppms-in-england-but-with-caveats/
NICE recommends Roche’s Tecentriq combo for certain lung cancer patientsCertain patients with untreated lung cancer in England have a new treatment option after cost-effectiveness body NICE made Share XNICE recommends Roche’s Tecentriq combo for certain lung cancer patientshttps://pharmaphorum.com/news/nice-recommends-roches-tecentriq-combo-for-certain-lung-cancer-patients/
NICE launches new tool to identify promising digital and medical techNICE has launched a new resource to help identify and support new health technologies for the UK health Share XNICE launches new tool to identify promising digital and medical techhttps://pharmaphorum.com/news/nice-launches-new-tool-to-identify-promising-digital-and-medical-tech/
Many patients still denied cancer drugs in UK, survey findsThe Institute for Cancer Research has called for action to improve access to innovative cancer treatments after a Share XMany patients still denied cancer drugs in UK, survey findshttps://pharmaphorum.com/news/many-patients-still-denied-cancer-drugs-in-uk-survey-finds/
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
